Search

Position of EHA on Clinical Trials

Jul 01 2013 Posted in Advocacy news

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

Learn more on the EHA Campus

EHA has developed EHA Campus courses related to previous EHA-LSHBT Virtual Hematology Updates. The aim of the courses is to add to your learning experience, making the information discussed during the webinars available in an interactive and engaging way.

European Research Initiative on CLL (ERIC)

ERIC is devoted to improving the outcome of patients with Chronic Lymphocytic Leukemia (CLL) and related diseases. The objectives of ERIC are to promote:

Research in all aspects of chronic lymphocytic leukemia and related diseases.

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Jun 10 2016 Posted in Press releases

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

National societies

EHA pursues close collaboration with the national hematology societies to ensure that the professional hematology community in Europe is served in the best possible way.

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Jun 14 2013

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.